CPG
BCRX icon

Cornerstone Planning Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cornerstone Planning Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$951 Hold
100
– – ﹤0.01% 1520
2026
Q1 		$903 Hold
100
– – ﹤0.01% 1497
2025
Q4 		$666 Buy
100
+52
+108% +$376 ﹤0.01% 1450
2025
Q3 		$7.18K Sell
48
-52
-52% -$433 ﹤0.01% 853
2025
Q2 		$836 Hold
100
– – ﹤0.01% 1165
2025
Q1 		$796 Hold
100
– – ﹤0.01% 1181
2024
Q4 		$801 Hold
100
– – ﹤0.01% 1012
2024
Q3 		$812 Buy
+100
New +$760 ﹤0.01% 985

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Cornerstone Planning Group's BCRX Position: Q2 2026 in Review

Cornerstone Planning Group held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 100 shares worth $951. The position accounts for ﹤0.01% of the portfolio, ranked #1520.

Cornerstone Planning Group first reported a position in BCRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $7.18K in Q3 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Cornerstone Planning Group held 100 shares of BioCryst Pharmaceuticals worth $951 as of Q2 2026.
  • Cornerstone Planning Group left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #1520 holding.
  • Cornerstone Planning Group first reported a position in BioCryst Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Cornerstone Planning Group's BioCryst Pharmaceuticals position peaked at $7.18K in Q3 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.